Collegium Pharmaceutical Inc. (354)
XMUN 
Summary
354 Chart
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why
COLL gains momentum as strong Jornay PM growth and the Azstarys acquisition boosted 2026 guidance, strengthening its ADHD franchise and revenue outlook.
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Collegium Pharmaceutical Inc. (354) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Collegium Pharmaceutical Inc. ever had a stock split?
Collegium Pharmaceutical Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Vikram Karnani CEO | XMUN Exchange | US19459J1043 ISIN |
| US Country | 357 Employees | - Last Dividend | - Last Split | 7 May 2015 IPO Date |
Overview
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative medicines for pain management. Since its establishment in 2002 and subsequent name change in 2003, the company has dedicated its efforts towards providing solutions for patients suffering from pain. Headquartered in Stoughton, Massachusetts, Collegium Pharmaceutical aims to introduce abuse-deterrent formulations that offer effective pain relief while addressing the significant concern of opioid misuse. The company's expertise lies in leveraging its technological advancements to develop medicines that are not only effective in managing severe and persistent pain but also in mitigating the risks associated with long-term opioid use.
Products and Services
- Xtampza ER
An abuse-deterrent, extended-release oral formulation of oxycodone designed for managing pain that requires daily, around-the-clock, long-term opioid treatment. By employing an abuse-deterrent mechanism, Xtampza ER provides an option for those in severe pain, simultaneously addressing concerns related to opioid misuse.
- Nucynta ER and Nucynta IR
These formulations of tapentadol come in both extended-release (ER) and immediate-release (IR) forms. They are intended for the management of acute, severe, and persistent pain, offering versatility in pain management strategies to accommodate different levels of pain severity and durations.
- Belbuca
A buccal film containing buprenorphine, designed for the treatment of pain. Belbuca offers an innovative delivery system that allows for the efficient and controlled release of buprenorphine, a potent opioid that can provide long-term relief from chronic pain.
- Symproic
An oral formulation of naldemedine aimed at treating opioid-induced constipation in adult patients with chronic non-cancer pain. Symproic addresses a common and often distressing side effect of long-term opioid use, thereby improving the quality of life for patients undergoing long-term opioid therapy.
